A New Approach for the Treatment of COPD and Lung Cancer using Inhaled Retrometabolic HSP90 Inhibitors

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1038895

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The inflammatory lung disease Chronic Obstructive Pulmonary Disease (COPD) is a major disease burden in Australia with over 1 million sufferers and being the fourth biggest killer. Lung cancer is one of the most difficult cancers to treat with 5-year survival rates being below 20%. There is a pressing need for new therapies to treat these diseases and this project will develop new drugs designed to inhibit an underlying mechanism present in both diseases, with minimal side-effects.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2015

Funding Scheme: Development Grants

Funding Amount: $638,310.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medicinal and Biomolecular Chemistry not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

chronic obstructive pulmonary disease (COPD) | drug delivery | drug design | lung cancer | medicinal chemistry | pharmacology

Related Links